- Home
- EDSA vs APLM Comparison
EDSA vs APLM Comparison
Compare EDSA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- APLM
- Stock Information
- Founded
- EDSA 2015
- APLM 2016
- Country
- EDSA Canada
- APLM United States
- Employees
- EDSA N/A
- APLM N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- EDSA Health Care
- APLM Finance
- Exchange
- EDSA Nasdaq
- APLM Nasdaq
- Market Cap
- EDSA 6.1M
- APLM 15.6M
- IPO Year
- EDSA N/A
- APLM N/A
- Fundamental
- Price
- EDSA $1.73
- APLM $9.75
- Analyst Decision
- EDSA Strong Buy
- APLM Strong Buy
- Analyst Count
- EDSA 1
- APLM 2
- Target Price
- EDSA $21.00
- APLM $425.00
- AVG Volume (30 Days)
- EDSA 30.8K
- APLM 107.4K
- Earning Date
- EDSA 02-07-2025
- APLM 02-15-2025
- Dividend Yield
- EDSA N/A
- APLM N/A
- EPS Growth
- EDSA N/A
- APLM N/A
- EPS
- EDSA N/A
- APLM N/A
- Revenue
- EDSA N/A
- APLM $2,101,000.00
- Revenue This Year
- EDSA N/A
- APLM N/A
- Revenue Next Year
- EDSA N/A
- APLM N/A
- P/E Ratio
- EDSA N/A
- APLM N/A
- Revenue Growth
- EDSA N/A
- APLM 70.54
- 52 Week Low
- EDSA $1.55
- APLM $6.50
- 52 Week High
- EDSA $5.99
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- APLM 50.39
- Support Level
- EDSA $1.73
- APLM $7.23
- Resistance Level
- EDSA $1.99
- APLM $8.88
- Average True Range (ATR)
- EDSA 0.19
- APLM 1.37
- MACD
- EDSA 0.02
- APLM 0.21
- Stochastic Oscillator
- EDSA 18.00
- APLM 57.91
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.